早中期高血压肾损害患者中医体质的临床研究
|
摘要
高血压肾损害指高血压病导致肾脏功能和结构的改变。美国肾脏数据系统(USRDS)的资料表明,高血压病一直是导致ESRD的第二位原因；多危险因素干预研究(MRFIT)资料显示,大约49%的ESRD是由高血压引起；截止到2002年,我国大约有高血压患者1.6亿人,高血压患病率为18.8%；我国全部透析患者中,约9.6%是由于高血压肾动脉硬化症引起。中医文献中,并无确切的病名与高血压肾损害相对应。目前中医对高血压肾损害的认识还存在着局限性、辨证不统一等问题。高血压肾损害患者的中医体质分型呈现何种分布规律,至今没有此方面的调查研究。
目的：本课题通过对33例早中期高血压肾损害患者的中医体质分布进行观察统计,旨在发现早中期高血压肾损害的中医体质学特点及内在规律,为探讨该病提供另一种途径,从而更好的完善中医药预防治疗高血压肾损害的理论,对临床也具有一定的指导意义。
方法：本课题采用北京中医药大学王琦教授设计的9种体质类型分类方法,对每个入选病例的进行现场填写调查问卷；以搜集到北京中医药大学东方医院33例早中期高血压肾损害患者的临床资料为依据,运用数据描述方法,对早中期高血压肾损害患者的中医体质特点及内在规律进行初步探讨。
结果：1、调查后按体质转化分小于主要体质分值,但转化分大于40分者,认为存在兼夹体质情况,所调查人群中基本存在一种或多种兼夹,其中有重复情况存在。2、初步判定,早中期高血压肾损害患者性别上与中医体质分布无相关性。
结论：1、9种中医体质分型中,早中期高血压肾损害最主要的体质类型为阴虚质,易感性较其它体质者均高；2、在兼夹体质和倾向体质中,气虚质在早中期高血压肾损害中出现率均为最高；其它体质均参与了该病发生发展；3、早中期高血压肾损害的发生发展,是以一种或几种体质为主,多种体质因素共同参与的结果。
Study on the traditional Chinese medical Constitution of hypertension nephrosclerosis (HN)
Hypertension nephrosclerosis (HN) refers to the change of kidney structu re and function caused by hypertension in clinical. The United States Renal Data System (USRDS) data show that,Hypertension has been the second reason lead the ESRD in United States. Research of Multiple risk factor interventio n (MRFIT)found that about 49% of ESRD caused by hypertension. Statistics of 2 002 show that,Adult prevalence of hypertension was 18.8% in china,and about 160 million people with hypertension patients in china.According to 1999 s tatistics,all Hemodialysis patients in China,9.6% of benign arteriolar neph rosclerosis Hypertension, there are no precise Name Correspondingly in the t raditional Chinese medicine,Traditional Chinese Medicine understanding of H ypertension nephrosclerosis,there are still limits, differentiation is not u niform and so on. Whether patients with Hypertension nephrosclerosis in whic h the human constitution and more.What distribution of traditional Chinese medical Constitution type,There has been no research in this area.
Objective:In this research, according to observe and statistic the TCM constitution about 33 cases of early and medial stages hypertension nephros clerosis, we try to found the characteristic and distributed rule of the TCM constitution of early and medial stages HN,To better perfect the theory of TCM prevention and treatment about HN, Also has provide some clinical Guide significance.
Method:The subject with Beijing University of Chinese Medicine Qi Wang Professors'9 constitution classification, and each of the selected cases we re filled out the questionnaire; In accordance with 33 early and medial stag es hypertension nephrosclerosis patients'clinic data provided by Dongfang h ospitals in Beijing and using the data description method, this study Discus sed the TCM constitution Features and distributed rule of early and medial stages hypertension nephrosclerosis.
Results:1. In accordance with the transformed scores is less than the main constitution scores,but the transformed scores is more than 40 points, that determine there are have and complex by constitution. In study populati on have existence one kind or several complex by constitution, and there hav e repeat existence; 2. Preliminary determination,There is no correlation in s ex and distributed rule of the TCM constitution.
Conclusions:1. In 9 kinds of TCM constitution, Qi stagnation constitutio n was the primary of early and medial stages hypertension nephrosclerosis, and susceptibility were higher than other constitutions; 2. Both in complex by constitution and prone to constitution,Qi deficiency is the highest occu rrence rate of early and medial stages hypertension nephrosclerosis, other c onstitution were participate occurrence and development of this disease;3. In the occurrence and development of early and medial stages HN, was the dev elopment of one or several constitution primarily, and various constitutio n factors common participation of results.
目的：本课题通过对33例早中期高血压肾损害患者的中医体质分布进行观察统计,旨在发现早中期高血压肾损害的中医体质学特点及内在规律,为探讨该病提供另一种途径,从而更好的完善中医药预防治疗高血压肾损害的理论,对临床也具有一定的指导意义。
方法：本课题采用北京中医药大学王琦教授设计的9种体质类型分类方法,对每个入选病例的进行现场填写调查问卷；以搜集到北京中医药大学东方医院33例早中期高血压肾损害患者的临床资料为依据,运用数据描述方法,对早中期高血压肾损害患者的中医体质特点及内在规律进行初步探讨。
结果：1、调查后按体质转化分小于主要体质分值,但转化分大于40分者,认为存在兼夹体质情况,所调查人群中基本存在一种或多种兼夹,其中有重复情况存在。2、初步判定,早中期高血压肾损害患者性别上与中医体质分布无相关性。
结论：1、9种中医体质分型中,早中期高血压肾损害最主要的体质类型为阴虚质,易感性较其它体质者均高；2、在兼夹体质和倾向体质中,气虚质在早中期高血压肾损害中出现率均为最高；其它体质均参与了该病发生发展；3、早中期高血压肾损害的发生发展,是以一种或几种体质为主,多种体质因素共同参与的结果。
Study on the traditional Chinese medical Constitution of hypertension nephrosclerosis (HN)
Hypertension nephrosclerosis (HN) refers to the change of kidney structu re and function caused by hypertension in clinical. The United States Renal Data System (USRDS) data show that,Hypertension has been the second reason lead the ESRD in United States. Research of Multiple risk factor interventio n (MRFIT)found that about 49% of ESRD caused by hypertension. Statistics of 2 002 show that,Adult prevalence of hypertension was 18.8% in china,and about 160 million people with hypertension patients in china.According to 1999 s tatistics,all Hemodialysis patients in China,9.6% of benign arteriolar neph rosclerosis Hypertension, there are no precise Name Correspondingly in the t raditional Chinese medicine,Traditional Chinese Medicine understanding of H ypertension nephrosclerosis,there are still limits, differentiation is not u niform and so on. Whether patients with Hypertension nephrosclerosis in whic h the human constitution and more.What distribution of traditional Chinese medical Constitution type,There has been no research in this area.
Objective:In this research, according to observe and statistic the TCM constitution about 33 cases of early and medial stages hypertension nephros clerosis, we try to found the characteristic and distributed rule of the TCM constitution of early and medial stages HN,To better perfect the theory of TCM prevention and treatment about HN, Also has provide some clinical Guide significance.
Method:The subject with Beijing University of Chinese Medicine Qi Wang Professors'9 constitution classification, and each of the selected cases we re filled out the questionnaire; In accordance with 33 early and medial stag es hypertension nephrosclerosis patients'clinic data provided by Dongfang h ospitals in Beijing and using the data description method, this study Discus sed the TCM constitution Features and distributed rule of early and medial stages hypertension nephrosclerosis.
Results:1. In accordance with the transformed scores is less than the main constitution scores,but the transformed scores is more than 40 points, that determine there are have and complex by constitution. In study populati on have existence one kind or several complex by constitution, and there hav e repeat existence; 2. Preliminary determination,There is no correlation in s ex and distributed rule of the TCM constitution.
Conclusions:1. In 9 kinds of TCM constitution, Qi stagnation constitutio n was the primary of early and medial stages hypertension nephrosclerosis, and susceptibility were higher than other constitutions; 2. Both in complex by constitution and prone to constitution,Qi deficiency is the highest occu rrence rate of early and medial stages hypertension nephrosclerosis, other c onstitution were participate occurrence and development of this disease;3. In the occurrence and development of early and medial stages HN, was the dev elopment of one or several constitution primarily, and various constitutio n factors common participation of results.
引文
[1]陈香美.高血压病引起的肾脏损害[J].中华肾脏病杂志,2005,21(10)：563-565.
[2]USRDS 2001 Annual Data Report. Atlas of end stage renal disease in the United States, national institutes of health, national institute of diabetes and digestive and kidney diseases [M].Bethesda, MD, US Renal Data System,2001.
[3]The multiple risk factor intervention trial research group. Mortality after 16 years for participants randomized to the multiple risk factor intervention trial[J]. Circulation,1996,94; 946-951.
[4]中华医学会肾脏病分会透析移植登记工作组.1999年度全国透析移植登记报告[J].中华肾脏病杂志,2001,17；77-78.
[5]付治卿,周聊生.高血压肾损害机制的探讨[J].《临床荟萃》,2004,19(8)：469-471.
[6]Cooperme. Pathogenesis, prevention and treatment of diabetic nephropathy [J]. Lancet,1998,352(6):213-219.
[7]Anderson WP, Kett MM, Stevenson KM, et al. Renovascular hypertension:str uctural changes in the renal vasculature [J].Hypertension,2000,36:648-652.
[8]STERZELRB, LUFTFC, GAOY, etal.Renal disease and the development of hyper tension in saltsensitive Dahl rats[J], KidneyInt.1988,33(6)1119-1129.
[9]Dzau VJ[J].Hypertens,1994,1(4); 3.
[10]Kashiwagi M, Shinozaki M.Hirakata H, et al. Locally activated Rennin angiotensin system associated with TGF-1 as a major factor for renal injury induced by chronic inhibi tion of ni tric oxide synthase in rats [J]. JAMSocNephrol, 2000,11:616-624.
[11]Lavoie P, Robitaille G, Agaharazii M, et al.Involvement of transforming growth factor beta in the pathogenesis of hypertension in rats with chronic
renal failure [J]. Hypertens,2004,22(7):80.
[12]高岩,程海,付玲.高血压肾硬化患者TGF-β1. t-PA. PAI-1变化的临床意义探讨[J].中国实用内科杂志,2003,23：162-163.
[13]Lavoie P, Robitaille G, Agharazii M, et al. Neutralization of transforming growth factor beta attenuates hypertension and prevents renal injury in uremic rats [J]. Hypertens,2005,23:1895-1903.
[14]Lebel M, Lariviere R.ndothelin-1 in chronic renal failure and hypertens ion.an J Physiol Pharmacol,2003,1:607-621.
[15]梁贤栋,刘龙民,朱喜英.血管紧张素转换酶2与高血压及其肾损害[J].齐鲁医学杂志,2009,24：463-464.
[16]Garcia-stan J, Ortiz MC,0'Valle F, et al.ffects of angiotensin conver ting enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide deficiency induced hpertension in rats[J]. Cli nSci,2006,110:227-233.
[17]WATSON R E, SUPOMIT S C, ZHAO H, et al.Role of seneory nervous system vasoactive peptides in hypertension[J]. Braz J Med Biol Res,2002,35:1035-1045.
[18]Uehara Y. PGD(2)/L-PGDS system in hypertension and renal injury [J]. Nipp on Yakurigaku Zasshi,2004,123:23-33.
[19]Miller SB, Martin DR, Kissane J, et al. Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats[J].AmJ Physiol,1994,266(1 Pt 2):F129-134.
[20]Yo Y, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor in the maintenance of renal structure:antiapoptotic action of HGF on epithelial cells[J]. Kidney Int,1998,54(4):1128-1138.
[21]贾汝汉,王学玉,胡海云等.PGE1治疗慢性肾功能不全临床疗效观察[J].中华肾脏病杂志,1990,6(6)：371-373.
[22]Palmer BE. Impaired renal autoregulation:implication for the genesis of hypertension and hypertension induced renal injury [J]. Am J Med Sci,2001,321: 388-400.
[23]Hill GS, Heudes D, Jacquot C, et al. Morphometric evidence for impairmen t of renal autoregulation in advanced essential hypertension[J]. Kidney Int, 2006,69:823-831.
[24]薛浩,刘国树.高血压肾损害及其药物治疗进展[J].中国药物应用与监测,2005,4：34-35.
[25]Kincaid-Smith P. Hypothesis:obesity and the insulin resistance syndrome play a major role in endstage renal failure attributed to hypertension and labelled hypertensive nephrosclerosis'[J]. Hyper tens,2004,22:1051-1055.
[26]Charlesworth JA. Kriketos AD.Jones JE et al. Insulin resistance and pos tp randial triglyceride levels in primary renal disease[J]. Metabolism:Clin ical&Experimental,2005; 4(6):821-828.
[27]刘颖,何金,刘志民等.胰岛素抵抗大鼠血糖正常阶段肾皮质血管内皮功能的改变[J].中国糖尿病杂志,2006,14：171-174.
[28]FliserD, Kielstein J T, Menne J.Insulin resistance and renal Disease[J]. Contributions to Nephrology,2006,151:203-211.
[29]E1-Atat FA, Stas SN, Me Farlane SI et al.The relation ship between hype rinsulinemia, hypertension and progress sive renal disease[J]. Am SocNephrol, 2004,15:2816-2827.
[30]Salomaa V, Stinson V, Kark JD, et al.A Association of fibrionytic param eters with early atherosclermsis.A therosclerosis Risk in Communities Study [J].Cireulation,1995,91(2):284-290.
[31]Rob son SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active 1L-1 beta, IL-6 and plasm activator inhibitors from monocytes in vitro[J]. Br J Haematol,1994,86:322-326.
[32]OdaT, KimuraM, KhishidaA, et al. Cell-to-cell interaction is required to induce proteinuria in situimmue complex glomerulonepritis[J]. J Lab Clin Me d,1998,132(2):112-123.
[33]叶建明,郁丽霞,卢国元等.高血压性肾损害患者内皮功能及血小板活化指标的测定及其临床意义[J],苏州大学学报(医学版)2009,29(1)：149-150.
[34]吴旭斌,杨成悌,余静等.炎症在高血压病患者肾功能损害中的作用[J].高血压杂志,2003,11：16-18.
[35]常晓铁,刘龙民.核因子-κB及炎症反应在原发性高血压肾损害中的作用[J].广东医学,2010,31(11)：1493-1494.
[36]成威,周胜华,张铭等.阿托伐他汀对高血压肾病蛋白尿及C-反应蛋白和白介素-6的影响[J].高血压杂志,2005,13：767-770.
[37]Elmarakby AA, Quigley JE, Pollock DM, et al. Tumor necrosis factor [alph a]blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt sensitive hyper tens ion [J].Hypertension,2006,47:557-5 62.
[38]韩瑞发,姚智,王林译.免疫肾脏病学2版,沈阳：辽宁科学技术出版社,2006：552-563.
[39]Liao YH, Wei YM, Wang M, etal. Autoantibodies against AT1 Receptor and α 1 Adrenergic receptor in patients with hypertension[J]. Hypertensres,2002, 25; 641-646.
[40]赵林双,廖玉华,王敏等.抗β1和M受体自身抗体和神经内分泌激素与高血压合并肾损害的关系[J].第二军医大学学报,2006,27(10)：1150.
[41]刘晓燕,钟一红,刘红,袁敏等.慢性肾脏病患者氧化应激状态及其相关影响因素[J].上海医学,2009,32(9)：789-790.
[42]Pavel P, Lucie R, Vinh Dam, et al. Apoptosis in target organs of hypert ension[J]. Hypertension,1995,26(4):642.
[43]Ana MRL, Olga F, Miguel AA, et al. Glomerular cell proliferation and apoptosis in uninephrectomized spontaneously hypertensive rats[J]. Kidney Int,1998, 54(suppl 68):s36.
[44]Griffin KA, Picken MM, Bidani AK. Class difference in the effects of calcium channel blockade in the kidney[J]. mode[J]. kidney Int,1999,55:1849.
[45]Cain AE, khalil RA. Pathophysiology of essential hypertension:Role of the pump, the vessel and the kidney[J]. Seminars in Nephrology,2002,22(1):3.
[46]Churchill PC, Churchill MC, Bidani AK, et al.Genetic susceptibility to hypertension induced renal damage in the rat.Evidence based on kidney speci fic genome transfer [J].J Clin Invest,1977,100(6):1373.
[47]尤丹瑜,万建新,吴可贵.高血压肾损害[J.中华高血压杂志,2007,15：275-276.
[48]徐岩,赵秀珍,赵振霄.高血压肾损害及肾实质性高血压胰岛素受体基因第8外显子多态性分析[J].中华肾脏病杂志,2003,19：123-124.
[49]熊友珍,王旋.高血压的危险因素及研究进展[J].湖南环境生物职业技术学院学报,2008,14(1)：7-10.
[50]BaylisC. Sexual dimorphism of the aging kidney:role of nitric oxide Deficiency. Physiology (Beth esda),2008,23:142-150.
[51]王海燕.肾脏病学(第二版).人民卫生出版社,2001,1144-1179.
[52]Sullivan JC, Sem prun-Prieto L, Boesen EI, et al. Sex and sex hormones influence the development of albuminuria and renal macrophage infiltration in spontaneously hypertensive rats[J]. Am J Physiol Regul Integr Comp Physio,2007,293(4)：R1573-1579.
[53]李伟,胡洪贞.高血压肾损害的危险因素及防治策略[J].肾脏病与透析肾移植杂志.2010,19：172-175.
[54]仲昱,王钢,倪斌.从脾肾认识高血压肾损害的发展演变规律[J].天津中医药,2005,22(2)：111-113.
[55]王济生,陈丽霞,赵旭涛,崔岩,金艳.高血压肾病的中西医防治[J].中国中西医结合肾病杂志,2001,2(10)：619.
[56]Parving HH, Jenser HA, Mogensen CE, et al.Increased urinary albuinin excretion rate in benign essential hyper tens ion[J]. Lancet,1974,1:1190.
[57]Cerasola G, Cot tone S, Dlgnoto G, et al. Microalbum inuria, renal dys function and cardiovascular comp lication in essential hypertension[J]. J Hy pertens,1996,14 (7):915-920.
[58]吴峻,孙明.两类尿蛋白对不同时期高血压肾损害的相关性研究[J].中国现代医学杂志,2002,12(16)：10-13.
[59]袁托亚,刘凤琴,曹中朝.高血压病与血尿β2微球蛋白的关系[J].中国实用内科杂志,1999,19(9)：549.
[60]Alderman MH, Melchar L,Drayer DE, et al.Increased excretion of urinary N-acetylbeta-gluco sam inidase in essential hypertension and it sdeline with antihypertensivet herapy[J].N Engl J Med,1983,309:1213.
[61]Ska lovaS. The diagnostic role of urinary N-acetyl-beta-D-glucosa-mini dase(NAG) activity in the detection of renal tubular impairment [J]. Act aMed ica(Hradec Kralove),2005,48(2):75-80.
[62]万莉莉,孙洞箫.尿蛋白及尿酶测定在高血压肾损害早期诊断的价值[J].中国保健(医学研究版),2007,15(4)：76-77.
[63]王飞,卜培莉.高血压早期肾损害的监测指标[J].心血管病学进展,2009,30(1)：80-81.
[64]Kyhse-Andersen J, Schmidt C, Nordin G, et al. Serum cystatin C, determined by a rapid, automated particleen hanced turbidimetric method, is a better marker than serum creatinine glomerular filt ration rate [J].Clin Chem,1994,40: 1921-1926.
[65]Filler G, Witt I, Priem F, et al.Are cystatin C and beta 2-m-icroglobul in better markers than serum creatinine for prediction of a normal glomerul ar filt ration rate in pediatric subjects [J].Clin Chem,1997,43:1077-1088.
[66]罗奇智,曾彩凤.血清胱抑素C对高血压早期肾损害的诊断价值[J].检验医学与临床,2010,7(2)：101-102.
[67]曹国良,乔永芳.轻中度高血压患者早期肾损害血清尿酸检测意义[J].中国综合临床,2005,21(5):391-393.
[68]Mule G, Cottone S, Cusimano P, et al. Inverse relationship between ambul atory arterial stiffness index and glomerular filtration rate in arterial h ypertension[J]. Am J Hypertens,2008,21(1):35-40.
[69]Ratto E, Leoncini G, Viazzi F, et al. Ambulatory arterial stiffness index and renal abnormalities in primary hypertension [J]. J Hypertens,2006,24(10): 2033-2038.
[70]王飞,卜培莉.高血压早期肾损害的监测指标[J].心血管病学进展,2009,30(1)：82.
[71]Mallion JM, Baguet JP, Siche JP, et al. Clinical value of ambulatory bl ood pressure monitoring[J].J Hypertens,1999,17 (5):585-595.
[72]李放,刘国仗,张晓锁等.高血压病患者动态血压及偶测血压与血、尿β2微球蛋白浓度的关系[J].中国循环,1996,11(6)：329-332.
[73]张盛霞,赵东太,宋晓冬,沈卫萍.脉压、脉压指数与原发性高血压肾损害早期的关系.中国康复理论与实践[J],2009,15(1)：83.
[74]BOhm M, Reil JC, Danchin N, et al. Association of heart rate with micro albuminuria in cardiovascular risk patients:data from I-SEARCH [J]. Hypert ension,2008,26(1):18-25.
[75]刘佳云,赵三明,杨晋红等.高血压病病人静息心率与早期肾脏损害关系的临床观察[J].中西医结合心脑血管病杂志,2007,5(5)：451-452.
[76]马云霞,马行一.ARB/ACEI在IgA肾病临床应用中的进展[J],西部医学,2009,21(3)：473.
[77]王艳霞,李波,于晓,刘瑞英,李淑雯.福辛普利对原发性高血压患者血压水平及肾功能指标的影响[J],山东医药,2010,50(39)：72-73.
[78]颜青松.金水宝胶囊联合贝那普利治疗高血压病早期肾损害疗效观察[J],中医药导报,2010,16(2)：20.
[79]马靖.ARB用于逆转原发性高血压早期肾损害临床探讨[J],药物与临床,2010,17(20)：66-67.
[80]林书典,周巧玲,詹锋,李文宁.福辛普利和缬沙坦对自发性高血压模型鼠肾损害 中的作用[J],中国热带医学,2010,10(6)：724-725.
[81]Staessen JA, Li Y, Thi js L, et al. Blood pressure reduction and card iovascular prevention[J]. secondary revention trial HypertensRes,2005,28(5):385-407.
[82]刘泽军,吴礼文,于长福.氨氯地平联合厄贝沙坦对高血压早期肾损害的防治作用[J],医学信息,2010,4：942-943.
[83]曲晓,吕艳红.贝尼地平对高血压肾损害患者的疗效观察[J],中国现代药物应用,2010,4(21)：161-162.
[84]郭晓玲,檀金川,王刚.中药药浴治疗维持性血液透析患者皮肤瘙痒症临床观察[J].中医中药,2009,16(4)：84.
[85]刘春卿.肾衰灌肠液治疗慢性肾衰300例[J].吉林中医,2007,27(10)：19.
[86]张春凤.中药灌肠治疗慢性肾功能衰竭湿浊证60例临床总结[J].吉林中医药,2006,26(2)：21.
[87]田其生,董吉.百令胶囊联合海昆肾喜胶囊治疗慢性肾衰竭疗效分析[J].中国社区医师·医学专业,2010,21(12)：180.
[88]扶桂升.金水宝胶囊联合降压药治疗高血压肾病35例临床观察[J].中医药导报,2009,15(9)：14-15.
[89]沈颖,刘华,李嵘等.前列腺素E1在慢性肾功能衰竭中的应用[J].中国实用医药,2009,4(33)：106.
[1]刘福明.试论肝肾阴虚痰瘀阻肾是高血压病肾损害病机关键[J].福建中医药,2004,35(2)：41-42.
[2]徐向青,郑三霞.高血压病肾损害病机简析[J].中医药学刊,2005,23(1)：312-313.
[3]李丽,钱海凌,黄琛.活血化瘀利水法治疗高血压病肾损害的体会[J].蛇志,2008,20(1)：70-71.
[4]许庆友,韩琳,秦建国.赵玉庸“肾络瘀阻”病机学说及临床应用[J].中华中医药杂志,2010,25(5)：702-704.
[5]杜林,秦应娟.补肾活血法治疗原发性高血压肾损害50例[J].辽宁中医杂志,2011,38(1)：113.
[6]张彬.论气虚血瘀在高血压肾损害发病过程中的作用[J].上海中医药大学学报,2005,19 (4)：9.
[7]仲昱,王刚,倪斌.从脾肾认识高血压肾损害的发展演变规律[J].天津中医药,2005,22(2)：111-113.
[8]刘家生,方琦,胡顺金,赵莉.脾肾同调治疗高血压肾损害临床观察.中国中医急症[J],2008,17(10)：1360-1361.
[9]郭兆安.高血压性肾损害(肾衰竭期)湿浊内蕴证的临床研究[J].中国中西医结合肾病杂志,2007,8(11)：664.
[10]曹爱琴,包菎.杨霓芝教授分期论治高血压肾病的经验介绍[J].新中医,2010,42(7)：138-139.
[11]王济生,陈丽霞,赵旭涛,崔岩,金艳.高血压肾病的中西医防治[J].中国中西医结合肾病杂志,2001,2(10)：619-620.
[12]王耀献,高菁.肾脏病中西医诊治.辽宁科学技术出版社,2005.374-385.
[13]朱喜英,梁贤栋,胡宗仁,常晓铁,刘龙民.益肾平肝方对高血压早期肾损害患者动态血压、肾功能及血管内皮功能的影响[J].中成药,2010,32(4)：545-547.
[14]段光堂,王慧敏,裴朝华等.补肾化瘀泄浊法为主治疗高血压性肾损害的临床观察[J].中国中医药科技,2010,17(5)：440-441.
[15]程广书.中西医结合治疗高血压肾损害112例[J].中医研究,2003,16(6)：29-30.
[16]何有为.益肾活血法治疗高血压肾损害临床观察[J].湖北中医杂志,2007,29(5)：32.
[17]顾健霞.周氏养肝益水颗粒减轻原发性高血压早期肾损害的作用观察[J].中医药临床杂志,2005,17(4)：373-374.
[18]张琪,朱建军,袁杰.保元灌肠液治疗高血压患者早期肾损害60例[J].南京中医药大学学报(自然科学版),2001,17(3)：189-190.
[19]孙春华,王有,刘雅熙.中药肾区渗透并常规治疗高血压性肾损害40例疗效观察[J].药物与临床,2009,16(5)：36-37.
[20]杨靖,邢彤,李春禄等.中医体质学说现代研究进展[J].长春中医学院学报, 2000,16(4)：601.
[21]马晓慧.中医体质学说理论与方法研究进展[J].上海中医药杂志,2000,(5)：47.
[22]朱伟,王丽华,欧阳钦.中医体质学说研究面临的问题[J].中国中医药信息杂志,2000,7(3)：11.
[23]刘良倚.中医体质学说的研究现状[J].江西中医药,2000,31(6)：55.
[24]王琦,盛增秀.中医体质学说[M].南京：江苏科技出版社,1982.15.
[25]陆云飞,钱彦方.首庙全国中医体质学说及腹诊研讨会学术总结[J].中西医结合杂志,1987,7(11)：702.
[26]王琦.中医体质学[M].北京：中国医药科技出版社,1995,297.
[27]宋红谱.体质分析与辨证论治[J].中医研究,1998,(4)：111.
[28]王前奔.论体质与证的关系[J].江苏中医,1992,(6)：18.
[29]匡调元.关于体质学说研究的若干问题[J].北京中医学院学报,1986,9(4)：18.
[30]何裕民.体质研究一现时代中西医学的最佳交融点[J].医学与哲学,1996,17(6)：288.
[31]王琦.国家自然科学基金资助“中医痰湿(肥胖)体质的基础研究”课题总结[A].见：王琦.王琦医学论文集[M].北京：中国大百科全书出版社,1994,82(5)：47.
[32]王前飞,王前奔.肥胖人痰湿型体质的分布及其与冠心病的关系[J].云南中医杂志,1992,13(2)：8.
[33]袁兆荣,袁杰.老年中风疾病与体质因素关系[J].山东中医杂志,1997,16(6)：16.
[34]陈荣升.100例中风患者体质与相关因素的调查[J].北京中医学院学报,1988,11(4)：601.
[35]成肇智.试论体质和病机[J].陕西中医学院学报,1990,13(3)：7.
[36]朱燕波,王琦,邓棋卫等.中医体质类型与高血压的相关性研究[J].中西医结合学报,2010,8(1)：41-44.
[37]王应鹏,王归真,殷彩桥等.不同年龄与性别之间高血压病患者血脂特点[J].第四军医大学学报.2006；27(19)：1782-1785.
[38]柳洪胜,白文戴中,王少杰.从体质论治原发性高血压病[J].中华中医药杂志,2010,25(6)：818-819.
[39]蔡光先,朱克俭,韩育明,孙惠兰.高血压病常见证候临床流行病学观察[J].中医杂志.1999,40(8)：492-493.
[1]中华医学会肾脏病分会透析移植登记工作组.1999年度全国透析移植登记报告[J].中华肾脏病杂志,2001,17；77-78.
[2]刘健.中医体质学说与中医疾病证治的思考[J].中国中医基础医学杂志,2009,15(4)：316-317.
[3]王琦,中医体质三论[J].北京中医药大学学报,2008,31(10)：653-655.
[4]王琦.中医体质学[M].北京：中国医药科技出版社,1995,297.
[5]宋红谱.体质分析与辨证论治[J].中医研究,1998,(4)：111.
[6]王琦.9种基本中医体质类型的分类及其诊断表述依据[J].北京中医药大学学报,2005,28(4)：1-9.
[7]王海燕.肾脏病学.第3版.北京：人民卫生出版社,2008,1662.
[8]卫生部心血管病防治中心.中国心血管病报告2005.中国大百科全书出版社,2006：84.
[9]中华人民共和国卫生部.中国居民营养与健康状况[J].中国心血管病研究杂志,2004,2(12)：919-922.
[10]焦淑芳.北京市居民高血压患病及流行趋势分析[J].中国公共卫生,2005,21(12)：1491-1492.
[11]刘伟佳,陈维清,罗不凡等.广州市城乡居民高血压相关影响因素分析[J].中国公共卫生,2007,23(1)：34-36.
[12]沈汉超.高血压肾病诊治进展.《心脑血管病防治》,2002,2(2)：5-7.
[13]种冠峰,相有章.中国高血压病流行病学及影响因素研究进展[J].中国公共卫生,2010,26(3)：301-302.
[14]孙宁玲.《中国高血压防治指南》2004年修订版的解读[J].高血压杂志,2005,13(6)：378-379.
[15]孙文武. 中医体质类型与糖尿病肾病相关性分析[J].北京中医药,2010,29(9)：687-688.
[16]刘福明.试论肝肾阴虚痰瘀阻肾是高血压病肾损害病机关键[J].福建中医药,2004,35(2)：41-42.
[17]徐向青,郑三霞.高血压病肾损害病机简析[J].中医药学刊,2005,23(1)：312-313.
[18]徐学功,虞婕,张燕等.10440例亚健康人群中医体质分型调查分析[J].光明中医,2010,25(3)：551-552.
[19]仲昱,王刚,倪斌.从脾肾认识高血压肾损害的发展演变规律[J].天津中医药,2005,22(2)：111-113.
[20]郭兆安.高血压性肾损害(肾衰竭期)湿浊内蕴证的临床研究[J].中国中西医结合肾病杂志,2007,8(11)：664.
[21]李丽,钱海凌,黄琛.活血化瘀利水法治疗高血压病肾损害的体会[J].蛇志,2008,20(1)：70-71.
[2]USRDS 2001 Annual Data Report. Atlas of end stage renal disease in the United States, national institutes of health, national institute of diabetes and digestive and kidney diseases [M].Bethesda, MD, US Renal Data System,2001.
[3]The multiple risk factor intervention trial research group. Mortality after 16 years for participants randomized to the multiple risk factor intervention trial[J]. Circulation,1996,94; 946-951.
[4]中华医学会肾脏病分会透析移植登记工作组.1999年度全国透析移植登记报告[J].中华肾脏病杂志,2001,17；77-78.
[5]付治卿,周聊生.高血压肾损害机制的探讨[J].《临床荟萃》,2004,19(8)：469-471.
[6]Cooperme. Pathogenesis, prevention and treatment of diabetic nephropathy [J]. Lancet,1998,352(6):213-219.
[7]Anderson WP, Kett MM, Stevenson KM, et al. Renovascular hypertension:str uctural changes in the renal vasculature [J].Hypertension,2000,36:648-652.
[8]STERZELRB, LUFTFC, GAOY, etal.Renal disease and the development of hyper tension in saltsensitive Dahl rats[J], KidneyInt.1988,33(6)1119-1129.
[9]Dzau VJ[J].Hypertens,1994,1(4); 3.
[10]Kashiwagi M, Shinozaki M.Hirakata H, et al. Locally activated Rennin angiotensin system associated with TGF-1 as a major factor for renal injury induced by chronic inhibi tion of ni tric oxide synthase in rats [J]. JAMSocNephrol, 2000,11:616-624.
[11]Lavoie P, Robitaille G, Agaharazii M, et al.Involvement of transforming growth factor beta in the pathogenesis of hypertension in rats with chronic
renal failure [J]. Hypertens,2004,22(7):80.
[12]高岩,程海,付玲.高血压肾硬化患者TGF-β1. t-PA. PAI-1变化的临床意义探讨[J].中国实用内科杂志,2003,23：162-163.
[13]Lavoie P, Robitaille G, Agharazii M, et al. Neutralization of transforming growth factor beta attenuates hypertension and prevents renal injury in uremic rats [J]. Hypertens,2005,23:1895-1903.
[14]Lebel M, Lariviere R.ndothelin-1 in chronic renal failure and hypertens ion.an J Physiol Pharmacol,2003,1:607-621.
[15]梁贤栋,刘龙民,朱喜英.血管紧张素转换酶2与高血压及其肾损害[J].齐鲁医学杂志,2009,24：463-464.
[16]Garcia-stan J, Ortiz MC,0'Valle F, et al.ffects of angiotensin conver ting enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide deficiency induced hpertension in rats[J]. Cli nSci,2006,110:227-233.
[17]WATSON R E, SUPOMIT S C, ZHAO H, et al.Role of seneory nervous system vasoactive peptides in hypertension[J]. Braz J Med Biol Res,2002,35:1035-1045.
[18]Uehara Y. PGD(2)/L-PGDS system in hypertension and renal injury [J]. Nipp on Yakurigaku Zasshi,2004,123:23-33.
[19]Miller SB, Martin DR, Kissane J, et al. Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats[J].AmJ Physiol,1994,266(1 Pt 2):F129-134.
[20]Yo Y, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor in the maintenance of renal structure:antiapoptotic action of HGF on epithelial cells[J]. Kidney Int,1998,54(4):1128-1138.
[21]贾汝汉,王学玉,胡海云等.PGE1治疗慢性肾功能不全临床疗效观察[J].中华肾脏病杂志,1990,6(6)：371-373.
[22]Palmer BE. Impaired renal autoregulation:implication for the genesis of hypertension and hypertension induced renal injury [J]. Am J Med Sci,2001,321: 388-400.
[23]Hill GS, Heudes D, Jacquot C, et al. Morphometric evidence for impairmen t of renal autoregulation in advanced essential hypertension[J]. Kidney Int, 2006,69:823-831.
[24]薛浩,刘国树.高血压肾损害及其药物治疗进展[J].中国药物应用与监测,2005,4：34-35.
[25]Kincaid-Smith P. Hypothesis:obesity and the insulin resistance syndrome play a major role in endstage renal failure attributed to hypertension and labelled hypertensive nephrosclerosis'[J]. Hyper tens,2004,22:1051-1055.
[26]Charlesworth JA. Kriketos AD.Jones JE et al. Insulin resistance and pos tp randial triglyceride levels in primary renal disease[J]. Metabolism:Clin ical&Experimental,2005; 4(6):821-828.
[27]刘颖,何金,刘志民等.胰岛素抵抗大鼠血糖正常阶段肾皮质血管内皮功能的改变[J].中国糖尿病杂志,2006,14：171-174.
[28]FliserD, Kielstein J T, Menne J.Insulin resistance and renal Disease[J]. Contributions to Nephrology,2006,151:203-211.
[29]E1-Atat FA, Stas SN, Me Farlane SI et al.The relation ship between hype rinsulinemia, hypertension and progress sive renal disease[J]. Am SocNephrol, 2004,15:2816-2827.
[30]Salomaa V, Stinson V, Kark JD, et al.A Association of fibrionytic param eters with early atherosclermsis.A therosclerosis Risk in Communities Study [J].Cireulation,1995,91(2):284-290.
[31]Rob son SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active 1L-1 beta, IL-6 and plasm activator inhibitors from monocytes in vitro[J]. Br J Haematol,1994,86:322-326.
[32]OdaT, KimuraM, KhishidaA, et al. Cell-to-cell interaction is required to induce proteinuria in situimmue complex glomerulonepritis[J]. J Lab Clin Me d,1998,132(2):112-123.
[33]叶建明,郁丽霞,卢国元等.高血压性肾损害患者内皮功能及血小板活化指标的测定及其临床意义[J],苏州大学学报(医学版)2009,29(1)：149-150.
[34]吴旭斌,杨成悌,余静等.炎症在高血压病患者肾功能损害中的作用[J].高血压杂志,2003,11：16-18.
[35]常晓铁,刘龙民.核因子-κB及炎症反应在原发性高血压肾损害中的作用[J].广东医学,2010,31(11)：1493-1494.
[36]成威,周胜华,张铭等.阿托伐他汀对高血压肾病蛋白尿及C-反应蛋白和白介素-6的影响[J].高血压杂志,2005,13：767-770.
[37]Elmarakby AA, Quigley JE, Pollock DM, et al. Tumor necrosis factor [alph a]blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt sensitive hyper tens ion [J].Hypertension,2006,47:557-5 62.
[38]韩瑞发,姚智,王林译.免疫肾脏病学2版,沈阳：辽宁科学技术出版社,2006：552-563.
[39]Liao YH, Wei YM, Wang M, etal. Autoantibodies against AT1 Receptor and α 1 Adrenergic receptor in patients with hypertension[J]. Hypertensres,2002, 25; 641-646.
[40]赵林双,廖玉华,王敏等.抗β1和M受体自身抗体和神经内分泌激素与高血压合并肾损害的关系[J].第二军医大学学报,2006,27(10)：1150.
[41]刘晓燕,钟一红,刘红,袁敏等.慢性肾脏病患者氧化应激状态及其相关影响因素[J].上海医学,2009,32(9)：789-790.
[42]Pavel P, Lucie R, Vinh Dam, et al. Apoptosis in target organs of hypert ension[J]. Hypertension,1995,26(4):642.
[43]Ana MRL, Olga F, Miguel AA, et al. Glomerular cell proliferation and apoptosis in uninephrectomized spontaneously hypertensive rats[J]. Kidney Int,1998, 54(suppl 68):s36.
[44]Griffin KA, Picken MM, Bidani AK. Class difference in the effects of calcium channel blockade in the kidney[J]. mode[J]. kidney Int,1999,55:1849.
[45]Cain AE, khalil RA. Pathophysiology of essential hypertension:Role of the pump, the vessel and the kidney[J]. Seminars in Nephrology,2002,22(1):3.
[46]Churchill PC, Churchill MC, Bidani AK, et al.Genetic susceptibility to hypertension induced renal damage in the rat.Evidence based on kidney speci fic genome transfer [J].J Clin Invest,1977,100(6):1373.
[47]尤丹瑜,万建新,吴可贵.高血压肾损害[J.中华高血压杂志,2007,15：275-276.
[48]徐岩,赵秀珍,赵振霄.高血压肾损害及肾实质性高血压胰岛素受体基因第8外显子多态性分析[J].中华肾脏病杂志,2003,19：123-124.
[49]熊友珍,王旋.高血压的危险因素及研究进展[J].湖南环境生物职业技术学院学报,2008,14(1)：7-10.
[50]BaylisC. Sexual dimorphism of the aging kidney:role of nitric oxide Deficiency. Physiology (Beth esda),2008,23:142-150.
[51]王海燕.肾脏病学(第二版).人民卫生出版社,2001,1144-1179.
[52]Sullivan JC, Sem prun-Prieto L, Boesen EI, et al. Sex and sex hormones influence the development of albuminuria and renal macrophage infiltration in spontaneously hypertensive rats[J]. Am J Physiol Regul Integr Comp Physio,2007,293(4)：R1573-1579.
[53]李伟,胡洪贞.高血压肾损害的危险因素及防治策略[J].肾脏病与透析肾移植杂志.2010,19：172-175.
[54]仲昱,王钢,倪斌.从脾肾认识高血压肾损害的发展演变规律[J].天津中医药,2005,22(2)：111-113.
[55]王济生,陈丽霞,赵旭涛,崔岩,金艳.高血压肾病的中西医防治[J].中国中西医结合肾病杂志,2001,2(10)：619.
[56]Parving HH, Jenser HA, Mogensen CE, et al.Increased urinary albuinin excretion rate in benign essential hyper tens ion[J]. Lancet,1974,1:1190.
[57]Cerasola G, Cot tone S, Dlgnoto G, et al. Microalbum inuria, renal dys function and cardiovascular comp lication in essential hypertension[J]. J Hy pertens,1996,14 (7):915-920.
[58]吴峻,孙明.两类尿蛋白对不同时期高血压肾损害的相关性研究[J].中国现代医学杂志,2002,12(16)：10-13.
[59]袁托亚,刘凤琴,曹中朝.高血压病与血尿β2微球蛋白的关系[J].中国实用内科杂志,1999,19(9)：549.
[60]Alderman MH, Melchar L,Drayer DE, et al.Increased excretion of urinary N-acetylbeta-gluco sam inidase in essential hypertension and it sdeline with antihypertensivet herapy[J].N Engl J Med,1983,309:1213.
[61]Ska lovaS. The diagnostic role of urinary N-acetyl-beta-D-glucosa-mini dase(NAG) activity in the detection of renal tubular impairment [J]. Act aMed ica(Hradec Kralove),2005,48(2):75-80.
[62]万莉莉,孙洞箫.尿蛋白及尿酶测定在高血压肾损害早期诊断的价值[J].中国保健(医学研究版),2007,15(4)：76-77.
[63]王飞,卜培莉.高血压早期肾损害的监测指标[J].心血管病学进展,2009,30(1)：80-81.
[64]Kyhse-Andersen J, Schmidt C, Nordin G, et al. Serum cystatin C, determined by a rapid, automated particleen hanced turbidimetric method, is a better marker than serum creatinine glomerular filt ration rate [J].Clin Chem,1994,40: 1921-1926.
[65]Filler G, Witt I, Priem F, et al.Are cystatin C and beta 2-m-icroglobul in better markers than serum creatinine for prediction of a normal glomerul ar filt ration rate in pediatric subjects [J].Clin Chem,1997,43:1077-1088.
[66]罗奇智,曾彩凤.血清胱抑素C对高血压早期肾损害的诊断价值[J].检验医学与临床,2010,7(2)：101-102.
[67]曹国良,乔永芳.轻中度高血压患者早期肾损害血清尿酸检测意义[J].中国综合临床,2005,21(5):391-393.
[68]Mule G, Cottone S, Cusimano P, et al. Inverse relationship between ambul atory arterial stiffness index and glomerular filtration rate in arterial h ypertension[J]. Am J Hypertens,2008,21(1):35-40.
[69]Ratto E, Leoncini G, Viazzi F, et al. Ambulatory arterial stiffness index and renal abnormalities in primary hypertension [J]. J Hypertens,2006,24(10): 2033-2038.
[70]王飞,卜培莉.高血压早期肾损害的监测指标[J].心血管病学进展,2009,30(1)：82.
[71]Mallion JM, Baguet JP, Siche JP, et al. Clinical value of ambulatory bl ood pressure monitoring[J].J Hypertens,1999,17 (5):585-595.
[72]李放,刘国仗,张晓锁等.高血压病患者动态血压及偶测血压与血、尿β2微球蛋白浓度的关系[J].中国循环,1996,11(6)：329-332.
[73]张盛霞,赵东太,宋晓冬,沈卫萍.脉压、脉压指数与原发性高血压肾损害早期的关系.中国康复理论与实践[J],2009,15(1)：83.
[74]BOhm M, Reil JC, Danchin N, et al. Association of heart rate with micro albuminuria in cardiovascular risk patients:data from I-SEARCH [J]. Hypert ension,2008,26(1):18-25.
[75]刘佳云,赵三明,杨晋红等.高血压病病人静息心率与早期肾脏损害关系的临床观察[J].中西医结合心脑血管病杂志,2007,5(5)：451-452.
[76]马云霞,马行一.ARB/ACEI在IgA肾病临床应用中的进展[J],西部医学,2009,21(3)：473.
[77]王艳霞,李波,于晓,刘瑞英,李淑雯.福辛普利对原发性高血压患者血压水平及肾功能指标的影响[J],山东医药,2010,50(39)：72-73.
[78]颜青松.金水宝胶囊联合贝那普利治疗高血压病早期肾损害疗效观察[J],中医药导报,2010,16(2)：20.
[79]马靖.ARB用于逆转原发性高血压早期肾损害临床探讨[J],药物与临床,2010,17(20)：66-67.
[80]林书典,周巧玲,詹锋,李文宁.福辛普利和缬沙坦对自发性高血压模型鼠肾损害 中的作用[J],中国热带医学,2010,10(6)：724-725.
[81]Staessen JA, Li Y, Thi js L, et al. Blood pressure reduction and card iovascular prevention[J]. secondary revention trial HypertensRes,2005,28(5):385-407.
[82]刘泽军,吴礼文,于长福.氨氯地平联合厄贝沙坦对高血压早期肾损害的防治作用[J],医学信息,2010,4：942-943.
[83]曲晓,吕艳红.贝尼地平对高血压肾损害患者的疗效观察[J],中国现代药物应用,2010,4(21)：161-162.
[84]郭晓玲,檀金川,王刚.中药药浴治疗维持性血液透析患者皮肤瘙痒症临床观察[J].中医中药,2009,16(4)：84.
[85]刘春卿.肾衰灌肠液治疗慢性肾衰300例[J].吉林中医,2007,27(10)：19.
[86]张春凤.中药灌肠治疗慢性肾功能衰竭湿浊证60例临床总结[J].吉林中医药,2006,26(2)：21.
[87]田其生,董吉.百令胶囊联合海昆肾喜胶囊治疗慢性肾衰竭疗效分析[J].中国社区医师·医学专业,2010,21(12)：180.
[88]扶桂升.金水宝胶囊联合降压药治疗高血压肾病35例临床观察[J].中医药导报,2009,15(9)：14-15.
[89]沈颖,刘华,李嵘等.前列腺素E1在慢性肾功能衰竭中的应用[J].中国实用医药,2009,4(33)：106.
[1]刘福明.试论肝肾阴虚痰瘀阻肾是高血压病肾损害病机关键[J].福建中医药,2004,35(2)：41-42.
[2]徐向青,郑三霞.高血压病肾损害病机简析[J].中医药学刊,2005,23(1)：312-313.
[3]李丽,钱海凌,黄琛.活血化瘀利水法治疗高血压病肾损害的体会[J].蛇志,2008,20(1)：70-71.
[4]许庆友,韩琳,秦建国.赵玉庸“肾络瘀阻”病机学说及临床应用[J].中华中医药杂志,2010,25(5)：702-704.
[5]杜林,秦应娟.补肾活血法治疗原发性高血压肾损害50例[J].辽宁中医杂志,2011,38(1)：113.
[6]张彬.论气虚血瘀在高血压肾损害发病过程中的作用[J].上海中医药大学学报,2005,19 (4)：9.
[7]仲昱,王刚,倪斌.从脾肾认识高血压肾损害的发展演变规律[J].天津中医药,2005,22(2)：111-113.
[8]刘家生,方琦,胡顺金,赵莉.脾肾同调治疗高血压肾损害临床观察.中国中医急症[J],2008,17(10)：1360-1361.
[9]郭兆安.高血压性肾损害(肾衰竭期)湿浊内蕴证的临床研究[J].中国中西医结合肾病杂志,2007,8(11)：664.
[10]曹爱琴,包菎.杨霓芝教授分期论治高血压肾病的经验介绍[J].新中医,2010,42(7)：138-139.
[11]王济生,陈丽霞,赵旭涛,崔岩,金艳.高血压肾病的中西医防治[J].中国中西医结合肾病杂志,2001,2(10)：619-620.
[12]王耀献,高菁.肾脏病中西医诊治.辽宁科学技术出版社,2005.374-385.
[13]朱喜英,梁贤栋,胡宗仁,常晓铁,刘龙民.益肾平肝方对高血压早期肾损害患者动态血压、肾功能及血管内皮功能的影响[J].中成药,2010,32(4)：545-547.
[14]段光堂,王慧敏,裴朝华等.补肾化瘀泄浊法为主治疗高血压性肾损害的临床观察[J].中国中医药科技,2010,17(5)：440-441.
[15]程广书.中西医结合治疗高血压肾损害112例[J].中医研究,2003,16(6)：29-30.
[16]何有为.益肾活血法治疗高血压肾损害临床观察[J].湖北中医杂志,2007,29(5)：32.
[17]顾健霞.周氏养肝益水颗粒减轻原发性高血压早期肾损害的作用观察[J].中医药临床杂志,2005,17(4)：373-374.
[18]张琪,朱建军,袁杰.保元灌肠液治疗高血压患者早期肾损害60例[J].南京中医药大学学报(自然科学版),2001,17(3)：189-190.
[19]孙春华,王有,刘雅熙.中药肾区渗透并常规治疗高血压性肾损害40例疗效观察[J].药物与临床,2009,16(5)：36-37.
[20]杨靖,邢彤,李春禄等.中医体质学说现代研究进展[J].长春中医学院学报, 2000,16(4)：601.
[21]马晓慧.中医体质学说理论与方法研究进展[J].上海中医药杂志,2000,(5)：47.
[22]朱伟,王丽华,欧阳钦.中医体质学说研究面临的问题[J].中国中医药信息杂志,2000,7(3)：11.
[23]刘良倚.中医体质学说的研究现状[J].江西中医药,2000,31(6)：55.
[24]王琦,盛增秀.中医体质学说[M].南京：江苏科技出版社,1982.15.
[25]陆云飞,钱彦方.首庙全国中医体质学说及腹诊研讨会学术总结[J].中西医结合杂志,1987,7(11)：702.
[26]王琦.中医体质学[M].北京：中国医药科技出版社,1995,297.
[27]宋红谱.体质分析与辨证论治[J].中医研究,1998,(4)：111.
[28]王前奔.论体质与证的关系[J].江苏中医,1992,(6)：18.
[29]匡调元.关于体质学说研究的若干问题[J].北京中医学院学报,1986,9(4)：18.
[30]何裕民.体质研究一现时代中西医学的最佳交融点[J].医学与哲学,1996,17(6)：288.
[31]王琦.国家自然科学基金资助“中医痰湿(肥胖)体质的基础研究”课题总结[A].见：王琦.王琦医学论文集[M].北京：中国大百科全书出版社,1994,82(5)：47.
[32]王前飞,王前奔.肥胖人痰湿型体质的分布及其与冠心病的关系[J].云南中医杂志,1992,13(2)：8.
[33]袁兆荣,袁杰.老年中风疾病与体质因素关系[J].山东中医杂志,1997,16(6)：16.
[34]陈荣升.100例中风患者体质与相关因素的调查[J].北京中医学院学报,1988,11(4)：601.
[35]成肇智.试论体质和病机[J].陕西中医学院学报,1990,13(3)：7.
[36]朱燕波,王琦,邓棋卫等.中医体质类型与高血压的相关性研究[J].中西医结合学报,2010,8(1)：41-44.
[37]王应鹏,王归真,殷彩桥等.不同年龄与性别之间高血压病患者血脂特点[J].第四军医大学学报.2006；27(19)：1782-1785.
[38]柳洪胜,白文戴中,王少杰.从体质论治原发性高血压病[J].中华中医药杂志,2010,25(6)：818-819.
[39]蔡光先,朱克俭,韩育明,孙惠兰.高血压病常见证候临床流行病学观察[J].中医杂志.1999,40(8)：492-493.
[1]中华医学会肾脏病分会透析移植登记工作组.1999年度全国透析移植登记报告[J].中华肾脏病杂志,2001,17；77-78.
[2]刘健.中医体质学说与中医疾病证治的思考[J].中国中医基础医学杂志,2009,15(4)：316-317.
[3]王琦,中医体质三论[J].北京中医药大学学报,2008,31(10)：653-655.
[4]王琦.中医体质学[M].北京：中国医药科技出版社,1995,297.
[5]宋红谱.体质分析与辨证论治[J].中医研究,1998,(4)：111.
[6]王琦.9种基本中医体质类型的分类及其诊断表述依据[J].北京中医药大学学报,2005,28(4)：1-9.
[7]王海燕.肾脏病学.第3版.北京：人民卫生出版社,2008,1662.
[8]卫生部心血管病防治中心.中国心血管病报告2005.中国大百科全书出版社,2006：84.
[9]中华人民共和国卫生部.中国居民营养与健康状况[J].中国心血管病研究杂志,2004,2(12)：919-922.
[10]焦淑芳.北京市居民高血压患病及流行趋势分析[J].中国公共卫生,2005,21(12)：1491-1492.
[11]刘伟佳,陈维清,罗不凡等.广州市城乡居民高血压相关影响因素分析[J].中国公共卫生,2007,23(1)：34-36.
[12]沈汉超.高血压肾病诊治进展.《心脑血管病防治》,2002,2(2)：5-7.
[13]种冠峰,相有章.中国高血压病流行病学及影响因素研究进展[J].中国公共卫生,2010,26(3)：301-302.
[14]孙宁玲.《中国高血压防治指南》2004年修订版的解读[J].高血压杂志,2005,13(6)：378-379.
[15]孙文武. 中医体质类型与糖尿病肾病相关性分析[J].北京中医药,2010,29(9)：687-688.
[16]刘福明.试论肝肾阴虚痰瘀阻肾是高血压病肾损害病机关键[J].福建中医药,2004,35(2)：41-42.
[17]徐向青,郑三霞.高血压病肾损害病机简析[J].中医药学刊,2005,23(1)：312-313.
[18]徐学功,虞婕,张燕等.10440例亚健康人群中医体质分型调查分析[J].光明中医,2010,25(3)：551-552.
[19]仲昱,王刚,倪斌.从脾肾认识高血压肾损害的发展演变规律[J].天津中医药,2005,22(2)：111-113.
[20]郭兆安.高血压性肾损害(肾衰竭期)湿浊内蕴证的临床研究[J].中国中西医结合肾病杂志,2007,8(11)：664.
[21]李丽,钱海凌,黄琛.活血化瘀利水法治疗高血压病肾损害的体会[J].蛇志,2008,20(1)：70-71.